Dehydration

Tastes Like Champagne, Feels Way Better: New Non-Alcoholic Wine 'Sparkling Blanc' from OJOY

Retrieved on: 
Wednesday, November 15, 2023
Holiday, Diet, Citrus, Glass, Wine, Amazon, Character, Collection, GREEN, Dehydration, Health, Friends, Hangover, Family, Set, Taste

GREEN BAY, Wis., Nov. 15, 2023 /PRNewswire/ -- OJOY Wine Company introduces Sparkling Blanc, the flagship offering in its collection of fine dealcoholized wines.

Key Points: 
  • GREEN BAY, Wis., Nov. 15, 2023 /PRNewswire/ -- OJOY Wine Company introduces Sparkling Blanc, the flagship offering in its collection of fine dealcoholized wines.
  • New OJOY Sparkling Blanc NA Wine is now available nationwide on Amazon and direct from OJOY Wine Company.
  • "When I stopped drinking alcohol, I found myself yearning for a high quality NA wine that tasted as good as ordinary wine," says OJOY Founder & CEO Marc Wendt.
  • OJOY offers two great options:
    Sparkling Blanc 4 Pack Limited Edition Gift Set, 355 mL Cans, Set of 2 Wine Tumblers ($59, drinkojoy.com )

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
NYHA, Cirrhosis, FDA, Research, Uric acid, Trial of the century, Deafness, Furosemide, Thrombosis, Erythema, Benign prostatic hyperplasia, Embolism, Internationalized domain name, Government, Hypoproteinemia, History, Kidney, Physician, Cerebral edema, Anuria, Bruise, Edema, Hepatic encephalopathy, Huber loss, Ototoxicity, Chronic kidney disease, Urinary retention, Congestion, Blood volume, Growth, Urine, Dehydration, Shanda, Diuresis, Pharmacy, Tinnitus, Medicaid, Azotemia, BUN, CO2, Oliguria, Organic acid, CKD, Investment, Patient, Creatinine, Heart failure, Hypersensitivity, Glucose, Coma, New York Heart Association Functional Classification, Ascites, Security (finance), Cryptocurrency, Pharmaceutical industry, Rare-earth element, Health insurance, Medical device, Video game, BURLINGTON

BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $3.8 million, and cost of product revenues were $1.1 million for the third quarter of 2023.
  • Research and development expenses were $3.4 million for the third quarter of 2023, compared to $3.7 million for the third quarter of 2022.
  • Selling, general and administrative expenses were $14.1 million for the third quarter of 2023, compared to $6.3 million for the third quarter of 2022.
  • As of September 30, 2023, scPharmaceuticals’ total shares outstanding was 35,859,045.
    scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2023 results today, Wednesday, November 8, at 4:30 p.m.

Pickle Juice® Participates in World's Largest Pickle Party

Retrieved on: 
Wednesday, November 8, 2023
Originality, Juice, Cramp, Power Plant Live!, Vitamin, Athlete, Dehydration, Mineral, Love, Pickle, Brine, Tullamore, Food preservation, Nightclub

MESQUITE, Texas, Nov. 8, 2023 /PRNewswire/ -- Pickle Juice®, the pioneer in providing scientifically proven methods to prevent muscle cramps and dehydration, has announced its participation and sponsorship of the upcoming World's Largest Pickle Party, which will be held on the 11th and 12th of November at Power Plant Live! In Baltimore.

Key Points: 
  • Additionally, attendees can take their pickle party experience to the next level by indulging in the newest offering from Pickle Juice, chasers, available for purchase exclusively at the Tullamore D.E.W.
  • He elaborates,"There's no better place to be than at the World's Largest Pickle Party.
  • Made up of a proprietary grain and blend of vinegar, Pickle Juice® works to block nerve signals that cause cramping.
  • Pickle Juice®  is available in a 1-gallon extra strength pickle juice, 16 ounce pickle juice sport, 8 ounce pickle juice sport, 2.5 ounce pickle juice shot and now chasers, as well as two flavors.

Intake Health Introduces New Hydration Testing Tech to Pro Sports

Retrieved on: 
Tuesday, November 7, 2023
National Science Foundation, NFL, Altitude, Social media, University of Colorado, Sport, Education, Hearing, NBA, Life, Inflow, Jaguars in Mesoamerican cultures, RD, National Institutes of Health, Research, NFL Network, Athlete, Jacksonville Jaguars, CBS Sports, MLB, Dehydration, Bender, Risk, Yahoo! Sports, MLS, SportsCenter, Basketball, Season, University, NIH, NHL, Citi Field, Safety, NCAA, NSF, Dietary supplement, Health

RALEIGH, N.C., Nov. 7, 2023 /PRNewswire/ -- Intake Health, a health technology company with cutting edge health monitoring research funded by both the National Science Foundation (NSF) and National Institute of Health (NIH), has made waves across sports in North America since officially launching it's InFlow hydration testing solution in August 2022.

Key Points: 
  • RALEIGH, N.C., Nov. 7, 2023 /PRNewswire/ -- Intake Health, a health technology company with cutting edge health monitoring research funded by both the National Science Foundation (NSF) and National Institute of Health (NIH), has made waves across sports in North America since officially launching it's InFlow hydration testing solution in August 2022.
  • Research grants won from the NIH and NSF helped Intake Health further pioneer their technology, which will include a toilet version.
  • With the NCAA and NBA basketball seasons kicking off shortly, Bender expects the Intake Health team will remain busy.
  • Beyond pro sports the InFlow technology is in use in facilities supporting military, first responders, as well as industrial health and safety settings around the world.

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Retrieved on: 
Friday, November 3, 2023
GMG, BioCryst Pharmaceuticals, FDA, Research, Patient, Drug design, IgA nephropathy, Plasma, CAD, Lupus nephritis, KLK5, Genetic disorder, RESEARCH, C2, DME, Eculizumab, Infection, Injection, Skin, Diabetes, Autoantibody, Ryan Murphy, Edema, Netherton, R, Autoimmune hemolytic anemia, HAE, Kallikrein, Growth, Disease, Dehydration, Muscle weakness, Immune system, Hemolysis, Solubility, Netherton syndrome, Clinical trial, Paratriathlon, Eye, Ravulizumab, Cold agglutinin disease, PARK, IP, SPINK5, Fine chemical, Pharmaceutical industry, Vaccine

A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com .

Key Points: 
  • A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com .
  • The team is excited to share our approach, and our expanded pipeline of new programs, at our R&D Day,” said Jon Stonehouse, president and chief executive officer of BioCryst.
  • The disease is caused by the deficiency of a natural inhibitor (SPINK5) of KLK5, a serine protease responsible for regulating skin shedding.
  • Netherton syndrome can be life threatening, especially during infancy when patients are vulnerable to dehydration and recurrent infections.

Bexacat™ (bexagliflozin tablets), the First and Only Tablet to Treat Feline Diabetes, Named “Overall Cat Health Product Of The Year” In 2023 Pet Innovation Awards

Retrieved on: 
Thursday, November 2, 2023
Science, FDA, Research, Retail, Veterinarian, NYSE, Innovation, Food, Diabetes, Vomiting, Human, Cat, Weight loss, Diarrhea, Elanco, Service, DM, SGLT2, Argyreia nervosa, Liver, Type 1 diabetes, Pancreatitis, ELAN, Urine, Dehydration, Disease, Risk, Farmer, Lethargy, Depression, Diabetic ketoacidosis, Pet, Diagnosis, Death, Glucose, Coma, Insulin, Pharmaceutical industry, Health, Housing

Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).

Key Points: 
  • Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).
  • “Bexacat removes some of the traditional challenges associated with treating feline diabetes and is a more efficient option for today’s on-the-go pet owner lifestyle.
  • Bexacat is needle-free and dosed to felines at a minimum weight of 6.6 lbs in order to ensure dosing accuracy.
  • The 2023 Pet Innovation Awards attracted more than 2,000 nominations from around the world.

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

Retrieved on: 
Tuesday, October 31, 2023
Rat, Research, Constipation, American College, Food, Northside Hospital, Prescription, Dehydration, Risk, New Drug Application, CKD, Human, Sale, MPH, Diarrhea, Jefferies Group, Journal, Chronic kidney disease, Irritable bowel syndrome, NDA, Safety, App, Investment, Patient, D, Fosun Pharma, IBS-C, Hyperphosphatemia, ACG, Growth, Clinical trial, SLR, Kyowa Kirin, FDA, Incidence, Conversation, Regulation of tobacco by the U.S. Food and Drug Administration, American College of Gastroenterology, Society, Death, Abdominal distension, Dialysis, Pharmaceutical industry, Fine chemical, Beauty salon, Video game, Nursing, Birth control, Health, Motility, RD

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • “Demonstrating consistent, quarter-over-quarter growth of IBSRELA prescriptions during the third quarter, we achieved a 22 percent increase in net sales revenue.
  • We have raised our full year U.S. net sales revenue guidance for IBSRELA, reflecting the important benefit this product is offering to patients.
  • Driven by increased demand for IBSRELA, the company reported net sales revenue of $22.3 million in the third quarter, 22 percent quarter-over-quarter growth compared to the second quarter of 2023.
  • Ardelyx currently expects full-year 2023 U.S. net product revenue for IBSRELA to be between $76.0 and $78.0 million.

The Evolved Co. Announces the Launch of PerformH2O Performance Water Powered by Below 33™ Frequency Technology

Retrieved on: 
Wednesday, November 1, 2023
LOS, Amazon (company), Dehydration, Water, Athlete, Printed circuit board, Satellite navigation device, Cement

LOS ANGELES, Nov. 1, 2023 /PRNewswire-PRWeb/ -- The Evolved Co., a trailblazer in innovative hydration solutions, proudly unveiled its leading product, PerformH2O Performance Water, fortified with proprietary Below

Key Points: 
  • The Evolved Co., a trailblazer in innovative hydration solutions, proudly unveiled its leading product, PerformH2O Performance Water, fortified with proprietary Below 33™ Frequency Technology.
  • LOS ANGELES, Nov. 1, 2023 /PRNewswire-PRWeb/ -- The Evolved Co. , a trailblazer in innovative hydration solutions, proudly unveiled its leading product, PerformH2O Performance Water , fortified with proprietary Below
  • "With PerformH2O and our Below 33 Frequency Technology, we're taking the effectiveness and benefits of proper hydration to a level previously unattainable."
  • PerformH2O Performance Water represents the culmination of extensive research and development, unveiling a game-changing innovation driven by the remarkable

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

Retrieved on: 
Monday, October 23, 2023
IBS-C, Rat, Bloating, Patient, Abdominal pain, Constipation, American College, Incidence, Food, MPH, Diarrhea, RD, ACG, Post hoc analysis, Duration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College of Gastroenterology, AS3, Death, Abdominal distension, Dehydration, Risk, Safety, Pain, Mayo Clinic, Human, Pharmaceutical industry, Birth control, CSBM, MD

“Physicians and other professionals attending ACG 2023 work with IBS-C patients every day and know all too well how challenging this condition can be.

Key Points: 
  • “Physicians and other professionals attending ACG 2023 work with IBS-C patients every day and know all too well how challenging this condition can be.
  • “While a significant proportion of patients will have an early positive response to IBSRELA treatment, patient response rates increase with continued therapy.
  • The researchers concluded that these patients experience a relatively quick onset of symptom relief under tenapanor treatment and that weekly response rates continued to increase with treatment duration.
  • IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Entrinsic Bioscience Announces Breakthrough Innovation for Next Generation Sports and Recreational Rehydration™ Beverages

Retrieved on: 
Tuesday, October 24, 2023
GI, Trial of the century, Sport, Exertion, EBS, Health, Inflammation, Permeability, Monash, Dehydration, Ultra, Monash University, Vaccine, Dietary supplement, MD

NORWOOD, Mass., Oct. 24, 2023 /PRNewswire/ -- Entrinsic Bioscience (EBS) has published a ground-breaking clinical study demonstrating the potential for next generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress. This formula also harnesses the power of eight times the number of electrolyte transporters resulting in more complete and faster rehydration. Unlike glucose-based beverages which utilize only one transporter, this formula will provide consumers superior electrolyte and water absorption with increased heat protection, immune support and inflammation reduction during exertional heat stress.

Key Points: 
  • This formula also harnesses the power of eight times the number of electrolyte transporters resulting in more complete and faster rehydration.
  • Unlike glucose-based beverages which utilize only one transporter, this formula will provide consumers superior electrolyte and water absorption with increased heat protection, immune support and inflammation reduction during exertional heat stress.
  • "We are excited to announce the results of this study demonstrating the potential to transform traditional sports and recreational beverages around the globe," stated Stephen Gatto, chairman and CEO of Entrinsic Bioscience.
  • New benefits delivered by the EBS amino acid-based beverages during the HEAAT study include:
    Protection of the intestinal barrier during sport, physical exertion and heat